Risk Minimisation Materials

Fabrazyme (agalsidase beta) - Home Infusion HCP Manual - Risk Minimisation Information for Healthcare Professionals

The objective of this document is to provide guidance to healthcare professionals for the management of patients receiving Fabrazyme (agalsidase beta) at home.

For Healthcare Professionals

Fabrazyme (agalsidase beta) - Home Infusion Patient Manual - Risk Minimisation Information for Patients

The objective of this document is to provide patients with guidance on how to receive Fabrazyme (agalsidase beta) at home. It is the responsibility of the treating physician to supply this material to patients only if the treating physician decides that the patient is eligible for home infusion treatment.

Fabrazyme® (agalsidase beta) - Healthcare Professional Letter- Risk Minimisation Information for Healthcare Professionals

For hard copies please contact our medical information department at 0845 372 7101 or email uk-medicalinformation@sanofi.com

For Healthcare Professionals

CHCs ANNEX 1_Direct HCP Communication

Direct Healthcare Professional Communication, to inform of the results of a Europe-wide review and the latest evidence on the risk of thromboembolism in association with certain combined hormonal contraceptives (CHCs).

For Healthcare Professionals

CHCs ANNEX 2_Checklist for Prescribers

Combined Hormonal Contraceptives - checklist for prescribers.

For Healthcare Professionals

CHCs ANNEX 3_Risk of Blood Clots with CHCs

Important Information for women about risk of blood clots with combined hormonal contraceptives.

CHCs ANNEX 4_CHCs Important Info for Women

Combined hormonal contraceptives: important information for women.

CHCs ANNEX 1_Direct HCP Communication

Direct Healthcare Professional Communication, to inform of the results of a Europe-wide review and the latest evidence on the risk of thromboembolism in association with certain combined hormonal contraceptives (CHCs).

For Healthcare Professionals

CHCs ANNEX 2_Checklist for Prescribers

Combined Hormonal Contraceptives - checklist for prescribers.

For Healthcare Professionals

CHCs ANNEX 3_Risk of Blood Clots with CHCs

Important Information for women about risk of blood clots with combined hormonal contraceptives.

CHCs ANNEX 4_CHCs Important Info for Women

Combined hormonal contraceptives: important information for women.

CHCs ANNEX 1_Direct HCP Communication

Direct Healthcare Professional Communication, to inform of the results of a Europe-wide review and the latest evidence on the risk of thromboembolism in association with certain combined hormonal contraceptives (CHCs).

For Healthcare Professionals

CHCs ANNEX 2_Checklist for Prescribers

Combined Hormonal Contraceptives - checklist for prescribers.

For Healthcare Professionals

CHCs ANNEX 3_Risk of Blood Clots with CHCs

Important Information for women about risk of blood clots with combined hormonal contraceptives.

CHCs ANNEX 4_CHCs Important Info for Women

Combined hormonal contraceptives: important information for women.

Letter to Healthcare Professionals

Letter to Healthcare Professionals regarding the presence of crystals on some Fencino transdermal patches.

For Healthcare Professionals

Reminder of the potentional risk of life-threatening harm from accidental exposure

For Healthcare Professionals

Direct Healthcare Professional Communication

Risk of mix-ups between insulin Fiasp® (fast-acting insulin aspart) and Tresiba® (basal insulin degludec)

For Healthcare Professionals

Flixabi Patient Alert Card

This Alert Card contains important safety information to be aware of before and during treatment with Flixabi. The 'Package Leaflet’ should also be read carefully before using this medicine.

Flixabi Patient Screening Sheet

This screening sheet is intended for use by any healthcare professional who are assessing patients being considered for infliximab therapy.

For Healthcare Professionals

Important information for healthcare professionals on safety and risk minimisation for infliximab

The purpose of this educational brochure is to inform HCPs on important selected risks to be aware of in order to promote the safe and effective use of the product and appropriate management. The brochure should be read carefully before prescribing, dispensing or administering Flixabi® to patients (adults or children) for approved indications.

For Healthcare Professionals